Serge Belanger Annabel Samimy George Lasezkay Annabel Samimy So just, I want to make sure we're clear with that. What the good the endpoints have necessarily changed as we go into Phase 3. But you're just looking right now at treatment burden. But for our Phase 2 trial, for our Phase 2 trial, we're looking at treatment burden and we're looking at duration as I said to set up the best design possible to go into Phase 3 with a fixed dosing schedule of CLS-AX, and obviously going to phase 3, unless the draft g ...